DMT surveillance ·
DMT Evidence Update: What is new — and what is not
Two newly surfaced papers: a broad systematic review of short-acting tryptamines and a small qualitative study of psychedelic-trial participation.
Bottom line
A modest evidence-page update is justified. Add the review as an umbrella reference and the qualitative paper as a methodological note. Neither changes the Atlas conclusions on DMT entities, recurring structures or extended-state DMT. No new DMTx results, preregistered entity comparisons or credible cross-person tests of recurring reported structures surfaced this week.
At a glance
- Research items
- 2
- With empirical findings
- 2
- Manuscript decisions
- 3
Tap a heading to open or close each section.
Research watch(2)
1. Pharmacological, clinical, and translational evidence for N,N-dimethyltryptamine, 5-MeO-DMT, and zalsupindole: a systematic review
Peer-reviewed systematic review · Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2026;150:111966
Evidence base: 51 clinical, pharmacological and preclinical publications. Search updated to 7 July 2026; two independent reviewers; risk-of-bias assessment. Peer-reviewed, open-access systematic review; no new participant dataset.
Empirical finding
N,N-DMT and 5-MeO-DMT show rapid, short-lived pharmacological profiles. Clinical evidence is most developed for depression; evidence in other conditions remains preliminary. Reported adverse effects commonly included nausea, headache and transient cardiovascular changes.
Authors' interpretation
Short-acting tryptamines may offer practical clinical advantages, but links among exposure, receptor activity, subjective experience and outcome remain insufficiently resolved.
What is genuinely new
A useful cross-compound consolidation of a rapidly expanding literature. It does not newly establish efficacy, phenomenological invariants or mechanisms.
What this contributes
Compound separation: the comparatively advanced Phase 2b result highlighted by the review concerns a proprietary 5-MeO-DMT formulation, not N,N-DMT. It must not be presented as evidence that ordinary DMT has equivalent efficacy.
Limits
Substantial heterogeneity across compounds, routes, populations and designs. Clinical and animal evidence are combined within a broad synthesis. No pooled participant sample or meta-analysis. The July search cut-off excludes later 2026 work.
Conflicts and transparency
A publisher record flags a competing-interest declaration, but its detailed wording was not available in the accessible abstract record; conflict appraisal remains incomplete pending the full declaration.
Editorial impact
Add as an umbrella reference in comparative pharmacology or clinical development. Do not use it to support entity claims, DMTx conclusions or the general statement that 'DMT works for depression.'
2. Participant experiences and recommendations for psychedelic clinical trials and future treatment delivery: a qualitative study with experts by experience from the Psychedelic Participant Advocacy Network
Peer-reviewed qualitative research · Frontiers in Psychiatry. Published 14 October 2026
Sample: four white UK advocacy-network members. Method: three focus groups plus a validation workshop. DMT relevance: three had joined depression trials involving psilocybin or N,N-DMT; no separate DMT subgroup.
Empirical finding
Participants described screening, allocation uncertainty, staff relationships, time-limited support and study ending as shaping experience. Some recalled disappointment, shame, loss or difficulty after formal support ended.
Authors' interpretation
Set and setting should include the whole research pathway: recruitment, expectations, dosing support, integration, the wider support network and post-study care.
What is genuinely new
The study treats the research protocol itself as part of psychedelic set and setting and translates participant perspectives into practical trial-design considerations. It is methodological evidence, not evidence about intrinsic DMT effects.
What this contributes
The research pathway is part of the setting. Add as a methodological note; it does not change the Atlas conclusions on DMT.
Limits
Extremely small, self-selected and demographically narrow sample. Retrospective group discussion may encourage convergence or inhibit disagreement. Mixed substances and clinical indications; no DMT-specific inference. Participants' advocacy involvement shaped both the questions and responses. No direct observation of facilitator behaviour or causal test of contextual effects.
Conflicts and transparency
Five authors were Beckley Psytech employees or contractors. The company helped conceive and design the study, participated in data collection and analysis, contributed to the submission decision and reviewed the manuscript. None of the four participants had taken part in a Beckley-sponsored trial.
Manuscript decisions(3)
| Decision | Action |
|---|---|
| Add (umbrella reference) | Collyer et al. systematic review in comparative pharmacology or clinical development; keep the 5-MeO-DMT Phase 2b result separate from N,N-DMT. |
| Add (methodological note) | Seynaeve et al. qualitative study: the research pathway as part of set and setting; no DMT-specific inference. |
| No change | Atlas conclusions on DMT entities, recurring structures and extended-state DMT. |
These bulletins are not medical, psychological or legal advice, and nothing here encourages the obtaining, possession or use of any controlled substance.